



Financial Tear Sheet

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from GSDIa, phenylketonuria (PKU), Wilson disease, and citrullinemia; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in OTC deficiency, which is in a Phase 1/2 clinical trial. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.

PRIMARY IR CONTACT


Jean Franchi
 Chief Financial Officer
Phone: 617-714-0709
E-mail: ir@dimensiontx.com
 (<mailto:ir@dimensiontx.com>)

STOCK INFORMATION

DMTX (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$1.05
Change (%)	▼ 0.1 (8.70%)
Volume	129,300
52 Week Low	\$1.10
Market Cap	\$26,295,681
Rolling EPS	-2.12
PE Ratio	0
Shares Outstanding	25,043,506

Data as of 05/26/17 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

RECENT PRESS RELEASES & EVENTS

May 10, 2017 - 8:01 a.m.

Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update

There are currently no events scheduled.

April 24, 2017 - 12:06 p.m.

Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting

March 09, 2017 - 7:30 a.m.

Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing

SEC FILINGS

Filing Date	Form
05/26/17	4
05/26/17	4
05/26/17	8-K
05/26/17	4